Business
Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment
Pediatric trial marks the second brain tumor trial of Moleculin's lead STAT3 inhibitor HOUSTON, June 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq:
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"Pediatric trial marks the second brain tumor trial of Moleculin's lead STAT3 inhibitor\n\n\nHOUSTON, June 2, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (\"Moleculin\" or the \"Company\"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and the first patient has been enrolled in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children. The study is being conducted at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta.\n\n \n \n \n \n \n \n\n \nWP1066 is the lead molecule in Moleculin's portfolio of immune stimulators and modulators of transcription. WP1066 has been shown in animal models to both stimulate a natural immune response, while also inhibiting the activated form of STAT3 (p-STAT3), a gene transcription factor that is considered a master regulator of tumor-related activity.\n\"p-STAT3 has long been considered an 'undruggable' target,\" commented Walter Klemp, Chairman and CEO of Moleculin. \"We've shown activity in patients with WP1220, one of the other molecules in this portfolio. This trial represents another opportunity to show that p-STAT3 is a viable target. We are honored to be a part of this effort to cure childhood brain tumors.\"\nAbout Moleculin Biotech, Inc.\nMoleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity, being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML; WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, being studied for brain tumors, pancreatic cancer and hematologic malignancies; and WP1220, an analog to WP1066, being studied for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Meta...